US7994686B2
(en)
|
2004-06-14 |
2011-08-09 |
Massachusetts Institute Of Technology |
Electrochemical methods, devices, and structures
|
US7872396B2
(en)
|
2004-06-14 |
2011-01-18 |
Massachusetts Institute Of Technology |
Electrochemical actuator
|
JP2008503059A
(ja)
|
2004-06-14 |
2008-01-31 |
マサチューセッツ・インスティテュート・オブ・テクノロジー |
電気化学的方法、デバイス、および構造体
|
US8247946B2
(en)
|
2004-06-14 |
2012-08-21 |
Massachusetts Institute Of Technology |
Electrochemical actuator
|
US7999435B2
(en)
|
2004-06-14 |
2011-08-16 |
Massachusetts Institute Of Technology |
Electrochemical actuator
|
US8785500B2
(en)
*
|
2006-03-22 |
2014-07-22 |
Icahn School Of Medicine At Mount Sinai |
Intranasal administration of ketamine to treat depression
|
JP2010534530A
(ja)
|
2007-07-26 |
2010-11-11 |
エントラ ファーマシューティカルズ,インコーポレイテッド |
薬物を供給するためのシステム及び方法
|
CA2709071C
(en)
|
2007-12-14 |
2016-11-15 |
Labogroup S.A.S. |
Delivering aerosolizable food products
|
US20110038807A1
(en)
*
|
2009-08-14 |
2011-02-17 |
Demitri Papolos |
Compositions and methods for treating bipolar disorder
|
US8337457B2
(en)
|
2010-05-05 |
2012-12-25 |
Springleaf Therapeutics, Inc. |
Systems and methods for delivering a therapeutic agent
|
EP2652324A2
(en)
|
2010-12-17 |
2013-10-23 |
Massachusetts Institute Of Technology |
Electrochemical actuators
|
US9073819B2
(en)
|
2011-06-30 |
2015-07-07 |
University Of South Florida |
Compositions, methods of use, and methods of treatment
|
US9650352B2
(en)
*
|
2011-10-14 |
2017-05-16 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Use of (2R, 6R)-hydroxynorketamine, (S)-dehydronorketamine and other stereoisomeric dehydro and hydroxylated metabolites of (R,S)-ketamine in the treatment of depression and neuropathic pain
|
KR20140136982A
(ko)
*
|
2012-03-12 |
2014-12-01 |
얀센 파마슈티카 엔.브이. |
치료-불응성 또는 치료-저항성 우울증 치료용 에스케타민
|
AU2013201492A1
(en)
*
|
2012-03-13 |
2013-10-03 |
Janssen Pharmaceutica Nv |
Esketamine for the treatment of treatment-refractory or treatment-resistant depression
|
WO2013149102A1
(en)
*
|
2012-03-30 |
2013-10-03 |
The General Hospital Corporation |
Compositions comprising scopolamine and ketamine in the treatment of depression
|
JP6722453B2
(ja)
*
|
2012-08-23 |
2020-07-15 |
スチュアート エル ウェグ |
抗不安薬組成物、製剤および使用方法
|
US8974365B2
(en)
*
|
2012-11-25 |
2015-03-10 |
Steven Richard Devore Best |
Treatment of thalamocortical dysrhythmia
|
CN111643449A
(zh)
*
|
2013-03-15 |
2020-09-11 |
詹森药业有限公司 |
S-盐酸氯胺酮的药物组合物
|
ES2745024T3
(es)
*
|
2013-03-15 |
2020-02-27 |
Janssen Pharmaceutica Nv |
Composición farmacéutica de clorhidrato de S-ketamina
|
JP6462663B2
(ja)
|
2013-04-12 |
2019-01-30 |
アイカーン スクール オブ メディシン アット マウント シナイ |
心的外傷後ストレス障害を処置するための方法
|
US20160106808A1
(en)
|
2013-05-13 |
2016-04-21 |
Icahn School Of Medicine At Mount Sinai |
Treatment of Mood and Anxiety Disorders
|
WO2015037248A1
(en)
*
|
2013-09-13 |
2015-03-19 |
National University Corporation Chiba University |
Application of r-ketamine and salt thereof as pharmaceuticals
|
CA2936809A1
(en)
|
2014-01-14 |
2015-07-23 |
Children's Hospital Medical Center |
Compositions comprising ketamine for treating an autism spectrum disorder
|
US11207316B2
(en)
|
2014-05-30 |
2021-12-28 |
West Virginia University |
Ketamine or dextromethorphan formulations and methods of use
|
WO2016025581A1
(en)
|
2014-08-13 |
2016-02-18 |
Janssen Pharmaceutica Nv |
Method for the treatment of depression
|
EP3193853A1
(en)
|
2014-09-15 |
2017-07-26 |
Janssen Pharmaceutica NV |
VAL66MET (SNP rs6265) GENOTYPE SPECIFIC DOSING REGIMENS AND METHODS FOR THE TREATMENT OF DEPRESSION
|
EP4227954A1
(en)
|
2014-09-23 |
2023-08-16 |
Icahn School of Medicine at Mount Sinai |
Systems and methods for treating a psychiatric disorder
|
WO2016109427A1
(en)
*
|
2014-12-31 |
2016-07-07 |
Icahn School Of Medicine At Mount Sinai |
Method of maintaining the anti-depressant effect of ketamine with lithium
|
US9844551B2
(en)
|
2015-01-14 |
2017-12-19 |
Children's Hospital Medical Center |
Compositions and methods for treatment of fragile X syndrome
|
WO2016172672A1
(en)
*
|
2015-04-24 |
2016-10-27 |
Icahn School Of Medicine At Mount Sinai |
Method for treating suicidal ideation
|
US20160332962A1
(en)
|
2015-05-13 |
2016-11-17 |
Janssen Pharmaceutica Nv |
(s)-csa salt of s-ketamine, (r)-csa salt of s-ketamine and processes for the preparation of s-ketamine
|
US20160338977A1
(en)
*
|
2015-05-20 |
2016-11-24 |
Janssen Pharmaceutica Nv |
Methods and kits for treating depression
|
EP3297620A4
(en)
*
|
2015-06-27 |
2019-01-09 |
Shenox Pharmaceuticals, LLC |
TRANSDERMAL DELIVERY SYSTEM FOR KETAMINE
|
WO2017041112A1
(en)
*
|
2015-09-04 |
2017-03-09 |
Cyprus Therapeutics, Inc. |
Ketamine and cytochrome p 450 inhibitor combinations
|
CN106562952B
(zh)
*
|
2015-10-09 |
2020-06-09 |
江阴安博生物医药有限公司 |
氯胺酮在治疗重性抑郁障碍中的应用
|
WO2017087691A1
(en)
|
2015-11-17 |
2017-05-26 |
The Trustees Of Columbia University In The City Of New York |
Pharmacological prophylactics against stress-induced affective disorders and their associated symptoms
|
IL263153B2
(en)
*
|
2016-05-25 |
2023-09-01 |
National Health Res Inst |
Method and composition to lower the psychotic and addictive disorder of ketamine
|
JP6996678B2
(ja)
|
2016-08-25 |
2022-02-15 |
バリドーズ インコーポレイテッド |
制御された医学的治療のためのシステムおよび方法
|
US9963435B2
(en)
|
2016-08-31 |
2018-05-08 |
Dart Neuroscience, Llc |
Compounds for therapeutic use
|
US20210113493A1
(en)
|
2016-11-30 |
2021-04-22 |
Philip E. Wolfson |
Ketamine for the treatment of menstrually related symptoms
|
EP3636281B1
(en)
*
|
2017-05-09 |
2023-11-01 |
Zhejiang University |
Method for treating depression, and pharmaceutical composition
|
CN108853502B
(zh)
*
|
2017-05-09 |
2024-06-14 |
浙江大学 |
治疗抑郁症的方法和药物组合物
|
CN115025227A
(zh)
*
|
2017-05-09 |
2022-09-09 |
浙江大学 |
联合用药治疗抑郁症的方法和药物组合物
|
CN115025224A
(zh)
*
|
2017-05-09 |
2022-09-09 |
浙江大学 |
T型钙离子通道抑制剂治疗抑郁症的方法和药物
|
US20200009081A1
(en)
|
2017-09-13 |
2020-01-09 |
Janssen Pharmaceutica N.V. |
Delivery Of Esketamine For The Treatment Of Depression
|
GB2571696B
(en)
|
2017-10-09 |
2020-05-27 |
Compass Pathways Ltd |
Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
|
US11622948B2
(en)
|
2017-11-09 |
2023-04-11 |
The Trustees Of Columbia University In The City Of New York |
Biomarkers for efficacy of prophylactic treatments against stress-induced affective disorders
|
WO2019099568A1
(en)
*
|
2017-11-14 |
2019-05-23 |
Bexson Biomedical, Inc. |
Systems, devices, formulations and methods for controlled drug delivery
|
BR112020012473A2
(pt)
|
2017-12-22 |
2020-11-24 |
Janssen Pharmaceuticals, Inc. |
escetamina para o tratamento da depressão
|
EP3505157B1
(en)
*
|
2017-12-29 |
2021-12-08 |
Celon Pharma S.A. |
Dry powder ketamine composition for pulmonary administration in treatment-resistant depression
|
JPWO2019160057A1
(ja)
|
2018-02-15 |
2021-02-04 |
国立大学法人千葉大学 |
炎症性疾患若しくは骨疾患の予防又は治療剤及び医薬組成物
|
WO2019183470A2
(en)
|
2018-03-22 |
2019-09-26 |
Incarda Therapeutics, Inc. |
A novel method to slow ventricular rate
|
AU2019262197A1
(en)
|
2018-05-04 |
2020-11-26 |
Perception Neuroscience, Inc. |
Methods of treating substance abuse
|
US11154537B2
(en)
|
2018-08-10 |
2021-10-26 |
Eleusis Therapeutics Us, Inc. |
Method of treatment for ketamine infusion
|
US10555917B1
(en)
*
|
2018-08-16 |
2020-02-11 |
BNIW Ventures LLC. |
Methods of treating a neurological or psychiatric disorder
|
WO2020041329A1
(en)
*
|
2018-08-20 |
2020-02-27 |
Yale University |
Combination therapy for treating or preventing depression or other mood diseases
|
EP3628313A1
(en)
*
|
2018-09-28 |
2020-04-01 |
Celon Pharma S.A. |
Ketamine composition for use in a method of treatment of depression by pulmonary administration
|
EP3860579A1
(en)
*
|
2018-10-05 |
2021-08-11 |
Clexio Biosciences Ltd. |
Dosage regime of esketamine for treating major depressive disorder
|
US20220008398A1
(en)
*
|
2018-11-21 |
2022-01-13 |
Certego Therapeutics |
Gaboxadol for reducing risk of suicide and rapid relief of depression
|
JP2022524008A
(ja)
*
|
2019-03-05 |
2022-04-27 |
ヤンセン ファーマシューティカルズ,インコーポレーテッド |
うつ病の治療のためのエスケタミン
|
AU2020259406A1
(en)
|
2019-04-17 |
2021-11-04 |
Compass Pathfinder Limited |
Treatment of depression and other various disorders with psilocybin
|
US10973780B2
(en)
|
2019-05-15 |
2021-04-13 |
Bexson Biomedical, Inc. |
Ketamine formulation for subcutaneous injection
|
WO2020232246A1
(en)
*
|
2019-05-15 |
2020-11-19 |
The Trustees Of Columbia University In The City Of New York |
Compositions and methods against stress-induced affective disorders and their associated symptoms
|
CA3140035A1
(en)
*
|
2019-05-31 |
2020-12-03 |
Celon Pharma S.A. |
An inhaler for electronically supervised parenteral administration of a pharmaceutical composition
|
JP2022542746A
(ja)
|
2019-05-31 |
2022-10-07 |
セロン ファーマ エス.アー. |
医薬組成物の電子的に監督された投与
|
EP3979985A4
(en)
*
|
2019-06-07 |
2023-05-03 |
Paxmedica, Inc. |
COMPOSITIONS AND METHODS FOR TREATMENT OF CENTRAL NERVOUS SYSTEM DISEASES
|
EP4052112A4
(en)
|
2019-06-09 |
2023-06-28 |
KBLV Medical, LLC |
Device and system for remote regulation and monitoring of drug delivery and method of same
|
US20220304980A1
(en)
*
|
2019-07-04 |
2022-09-29 |
SW Holdings, Inc |
Metered dosing compositions and methods of use of psychedelic compounds
|
WO2021067702A1
(en)
*
|
2019-10-02 |
2021-04-08 |
Praxis Precision Medicines, Inc. |
Combinations of gaba-a receptor positive allosteric modulators and nmda antagonists, nmda negative allosteric modulators or nmda partial agonists
|
WO2021074448A1
(en)
|
2019-10-18 |
2021-04-22 |
Institute Of Science And Technology Austria |
Stimulation of neuronal plasticity
|
KR20220137033A
(ko)
*
|
2020-01-22 |
2022-10-11 |
실로스 테라퓨틱스, 인크. |
부작용이 감소된 nmda 길항제
|
WO2021231905A1
(en)
*
|
2020-05-15 |
2021-11-18 |
The University Of Kansas |
Ketamine treatment for amyotrophic lateral sclerosis
|
KR20230028244A
(ko)
|
2020-05-20 |
2023-02-28 |
썰테고 테라퓨틱스 아이엔씨. |
고리 중수소화 가복사돌 및 정신 장애의 치료를 위한 이의 용도
|
CN114306219B
(zh)
*
|
2020-09-30 |
2023-09-26 |
四川普锐特药业有限公司 |
稳定的r-氯胺酮药物组合物
|
JP2023551145A
(ja)
|
2020-11-18 |
2023-12-07 |
ベクソン バイオメディカル,インク. |
医薬化合物の錯化剤塩製剤
|
TW202310825A
(zh)
*
|
2021-05-14 |
2023-03-16 |
美商西羅斯醫療公司 |
減少nmda受體拮抗劑之副作用
|
WO2022241214A1
(en)
*
|
2021-05-14 |
2022-11-17 |
Seelos Therapeutics, Inc. |
Methods of using nmda receptor antagonists
|
KR20240012563A
(ko)
*
|
2021-05-26 |
2024-01-29 |
마인드셋 파마 인크. |
환각제-지방산 조합
|
US11984211B2
(en)
|
2021-08-30 |
2024-05-14 |
Isaac Abadi |
System and method for utilization of data from remote regulation and monitoring of drug delivery
|
WO2023207730A1
(zh)
*
|
2022-04-26 |
2023-11-02 |
宜昌人福药业有限责任公司 |
R-氯胺酮液体制剂及其用途
|
US20240065989A1
(en)
*
|
2022-08-31 |
2024-02-29 |
Zyvran Pharmaceuticals |
Method and composition for treating treatment resistant depression
|